Shitalkumar Patil

Shitalkumar Patil

Auto-generated profile, based on publicly available information

Shitalkumar Patil

Dr. J. J. Magdum Pharmacy College, Jaysingpur, Maharashtra, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2020 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
SHSandip M. Honmane
Sandip M. Honmane
SCSagar Maruti Chimane
Sagar Maruti Chimane
SBSandip Akaram Bandgar
Sandip Akaram Bandgar
SPShitalkumar Shivagonda Patil
Shitalkumar Shivagonda Patil

30 August 2024 in Asian Journal of Chemistry
Verified
Journal Article
Open access
PDF file
MSMayuresh Shinde
Mayuresh Shinde
SPShitalkumar Patil
Shitalkumar Patil
NBNeela Bhatia
Neela Bhatia
MBManish Bhatia
Manish Bhatia
In this work, the bioactivity of fatty acyl (amide) amino acid alkyl esters through cytotoxicity and DNA cleavage properties were assessed. The synthetic method utilized HBTU-catalyzed amide formation between the carboxyl group of stearic acid and linoleic acid and the amine group in L-glutamic acid dimethyl ester and L-methionine methyl ester. The conjugates were elucidated using FTIR, NMR and mass and evaluated for cytotoxicity (COLO-205, A549 cell lines). Conjugates 10a-c exhibited selective growth inhibitory effects on cancer cell lines, while no impact was detected on normal cells. Overall, there was a significant reduction in the proliferation of human colorectal (COLO-205) and lung cancer (A549) cancer cells. Conjugates 10a-c also exhibited favourable cytocompatibility on normal murine fibroblast (L929) cells. Conjugate 10c showed promiscuous in vitro cytotoxicity against colorectal (COLO-205) and lung (A549) cancer cells compared to conjugates 10a and 10b.

17 May 2025 in Asian Journal of Research in Medical and Pharmaceutical Sciences
Verified
Journal Article
Closed access
SPShitalkumar Patil
Shitalkumar Patil
VNVandana Narvekar
Vandana Narvekar
VPVrushabh Patil
Vrushabh Patil
RMRamling Mali
Ramling Mali
APAishwarya Patil
Aishwarya Patil
Introduction: Clitoria ternatea, a medicinal plant, has been traditionally used for its various therapeutic properties, including antifungal, anti-inflammatory, and antioxidant effects. The present study aimed to evaluate the antifungal potential of Clitoria ternatea seed extract incorporated into a cream formulation, with an emphasis on phytochemical screening, antifungal activity, and formulation characterization. Materials and Methods: The Clitoria ternatea seeds were collected, extracted using water and methanol, and subjected to various phytochemical tests to detect alkaloids, flavonoids, tannins, phenols, and amino acids. The cream formulations were prepared as oil-in-water (O/W) emulsions, incorporating Gokarn and a mixture of plant extracts. Antifungal activity was evaluated by the disc diffusion method, testing against Candida albicans (ATCC 90028). The prepared creams were assessed for parameters such as appearance, pH, homogeneity, spreadability, irritancy, and washability. Results: Phytochemical analysis confirmed the presence of alkaloids, flavonoids, tannins, phenols, and amino acids in the Clitoria ternatea extract. FTIR studies revealed characteristic functional groups in the extract and the formulation. Antifungal testing showed that the cream with Gokarn exhibited a significant zone of inhibition, though smaller than the positive control (marketed antifungal cream). The cream formulations were homogeneous, non-irritating, and easily spreadable, with satisfactory emolliency and washability. Conclusion: The results suggest that Clitoria ternatea seed extract possesses significant antifungal potential. The formulated cream showed promising results, with good physical properties and therapeutic potential for skin-related conditions. Further clinical studies are recommended to optimize the formulation for broader applications.

1 September 2026 in Current Advances in Medicine
Verified
Journal Article
Closed access
PDF file
PTPranil Toraskar
Pranil Toraskar
PPPravin Pawar
Pravin Pawar
VPVrushabh Patil
Vrushabh Patil
SPShitalkumar Patil
Shitalkumar Patil
Introduction: Diabetic retinopathy and inherited retinal dystrophies cause significant vision impairment globally and are grouped under ocular retinopathies. While traditional therapies are less effective as they only offer symptomatic relief, they run the risk of the disease progressing even further. The advent of the CRISPR-Cas9 gene editing system has the potential to allow the direct disease modification and correction of the diseased state of the gene. Therefore, a paradigm shift can occur where traditional therapies only offer symptomatic relief and disease modification can be offered instead. The objective of this article is to describe the current state of CRISPR-Cas9 for ocular retinopathies from the perspective of disease modification, and incorporate potential barriers to design a framework to assess the future opportunities and obstacles to the CRISPR-Cas9 gene editing system in the clinic. Methods: CRISPR 'Cas9', retinal 'gene editing', 'inherited retinal diseases', 'delivery systems', and a combination of these terms were employed when searching published literature. Studies were published in English, were original research, reviews, or clinical trials, and were peer-reviewed. Studies were excluded if they were not related to the ocular applications of CRISPR. Results: Results from pre-clinical studies or early-stage trials indicate that CRISPR-Cas9 may be used to restore the function of diseased retina and stabilize the further progression of the disease. Delivery systems are becoming more efficient and less likely to elicit immune responses. The expected therapeutic result is higher when all these systems are combined. Next-generation CRISPR editors, together with AI-based RNA design and delivery systems, are expected to improve the editing of the 'epigenome'. Discussion: The combination of CRISPR-Cas9 with cell-based therapies and personalized medicine approaches will continue to improve the precision and effectiveness of a given treatment. Advanced technologies in the field of gene modification and editing, AI-guided RNA therapies, and epigenome editing continue to remove obstacles related to specificity and expand the treatable areas in medicine. Conclusion: The potential of CRISPR-Cas9 in the treatment of Ocular Retinopathies is high given its ability to treat diseases by repairing their genetic causes. Continued off-target and delivery challenges and the slow pace of regulations will hinder the privileged work of multidisciplinary teams that are focused on the potential of CRISPR technologies. The long-term restoration of vision to patients who suffer from Retinal Diseases and improving their vision is not only the goal, but one of the more certain outcomes of this work.